Skip to main content
Log in

Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Ten patients in acute exacerbation of multiple sclerosis were treated with 1000 mg of methylprednisolone for 7 days, followed by abrupt cessation of therapy. The function of hypothalamic-pituitary-adrenal (HPA) axis was assessed by the response of ACTH and Cortisol to insulin tolerance test (ITT). ITT was performed 1 day before and 1, 3, 8, 13 and 23 days after the termination of the therapy (days 0, 8, 10, 15, 20 and 30 of the study, respectively). The response of these hormones to insulin-induced hypoglycemia prior to therapy was normal. There was no suppression of the ACTH response to hypoglycemia after the methylprednisolone therapy based on the 100% rise of ACTH after ITT. Cortisol response during ITT was suppressed at day 8 (1 day after ending of therapy) but recovered on day 10 (3 days after ending of therapy). In conclusion, 7 day-therapy with 1000 mg methylprednisolone does not result in the permanent suppression of the HPA axis, suggesting that no regular supplemental corticosteroid coverage is required. The observed transitory suppression of the HPA axis recovered spontaneously after the therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Troiano R., Cook S.D., Dowling P.C. Steroid therapy in multiple sclerosis. Point of view. Arch. Neurol. 44: 803, 1987.

    Article  CAS  PubMed  Google Scholar 

  2. Barnes M.P., Bateman D.E., Cleland P.G., Dick D.J., Walls T.J., Newman P.K. Intravenous methylprednisolone for multiple sclerosis in relapse. J. Neurol. Neurosurg. Psychiatr. 48: 157, 1985.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G.F., Perla F., Delsedime M., Gusmaroli G., Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlation. Neurology 36: 238, 1986.

    Article  CAS  PubMed  Google Scholar 

  4. Streeten D.H.P., Anderson G.H., Dalakos T.G., Seeley D., Mallov J.S., Eusebio R., Sunderlin F.S., Badawy S.Z.A., King R.B. Normal and abnormal function of the hypothalamic-pituitary-adrenocortical system in man. Endocr. Rev. 5: 371, 1984.

    Article  CAS  PubMed  Google Scholar 

  5. Lević Z., Mavra M., Manojlović D., Nikolić J., Subotić N. Cortisol and ACTH levels in plasma of MS patients treated with high-dose methylprednisolone intravenously. In: Meyer-Rienecker H., Olischer R.M. (Eds.), Actual aspects of multiple sclerosis. Progress in MS research. Rostock, Wilchelm-Pieck-Universitat, 1988, p. 123.

    Google Scholar 

  6. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis. Guidelines for research protocol. Ann. Neurol. 13: 227, 1983.

    Article  CAS  PubMed  Google Scholar 

  7. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology (Cleveland) 33: 1444, 1983.

    Article  CAS  Google Scholar 

  8. Wass J.A.H., Besser G.M. Tests of pituitary function. In: De Groot L.J. (Ed.), Endocrinology. W.B. Saunders Company, Philadelphia, 1989, p. 492.

    Google Scholar 

  9. Orth D.N., Kovacs W.J., DeBold C.R. The adrenal cortex. In: Wilson J.D., Foster D.W. (Eds.), William’s Textbook of Endocrinology. W.B. Saunders Company, Philadelphia, 1992, p. 489.

    Google Scholar 

  10. Swartz S.L., Dluhy R.G. Corticosteroids: Clinical pharmacology and therapeutic use. Drugs 16: 238, 1978.

    Article  CAS  PubMed  Google Scholar 

  11. Miro J., Amado J.A., Pesquera C., Lopez-Cordovilla J.J., Berciano J. Assessment of the hypothalamic-pituitary-adrenal axis function after corticosteroid therapy for MS relapses. Acta Neurol. Scand. 81: 534, 1990.

    Article  Google Scholar 

  12. Trotter J.L., Garvey W.F. Prolonged effects of large dose methylprednisolone infusion in multiple sclerosis. Neurology 30: 702, 1980.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lević, Z., Micić, D., Nikolić, J. et al. Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J Endocrinol Invest 19, 30–34 (1996). https://doi.org/10.1007/BF03347855

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347855

Key-words

Navigation